TY - JOUR
T1 - Determining the frequency of pathogenic germline variants from exome sequencing in patients with castrate-resistant prostate cancer
AU - Hart, Steven N.
AU - Ellingson, Marissa S.
AU - Schahl, Kim
AU - Vedell, Peter T.
AU - Carlson, Rachel E.
AU - Sinnwell, Jason P.
AU - Barman, Poulami
AU - Sicotte, Hugues
AU - Eckel-Passow, Jeanette E.
AU - Wang, Liguo
AU - Kalari, Krishna R.
AU - Qin, Rui
AU - Kruisselbrink, Teresa M.
AU - Jimenez, Rafael E.
AU - Bryce, Alan H.
AU - Tan, Winston
AU - Weinshilboum, Richard
AU - Wang, Liewei
AU - Kohli, Manish
PY - 2016
Y1 - 2016
N2 - Objectives: To determine the frequency of pathogenic inherited mutations in 157 select genes from patients with metastatic castrate-resistant prostate cancer (mCRPC). Design: Observational. Setting: Multisite US-based cohort. Participants: Seventy-one adult male patients with histological confirmation of prostate cancer, and had progressive disease while on androgen deprivation therapy. Results: Twelve patients (17.4%) showed evidence of carrying pathogenic or likely pathogenic germ line variants in the ATM, ATR, BRCA2, FANCL, MSR1, MUTYH, RB1, TSHR and WRN genes. All but one patient opted in to receive clinically actionable results at the time of study initiation. We also found that pathogenic BRCA2 variants appear to be enriched in mCRPC compared to familial prostate cancers. Conclusions: Pathogenic variants in cancer susceptibility genes are frequently observed in patients with mCRPC. A substantial proportion of patients with mCRPC or their family members would derive clinical utility from mutation screening. Trial registration number: NCT01953640; Results.
AB - Objectives: To determine the frequency of pathogenic inherited mutations in 157 select genes from patients with metastatic castrate-resistant prostate cancer (mCRPC). Design: Observational. Setting: Multisite US-based cohort. Participants: Seventy-one adult male patients with histological confirmation of prostate cancer, and had progressive disease while on androgen deprivation therapy. Results: Twelve patients (17.4%) showed evidence of carrying pathogenic or likely pathogenic germ line variants in the ATM, ATR, BRCA2, FANCL, MSR1, MUTYH, RB1, TSHR and WRN genes. All but one patient opted in to receive clinically actionable results at the time of study initiation. We also found that pathogenic BRCA2 variants appear to be enriched in mCRPC compared to familial prostate cancers. Conclusions: Pathogenic variants in cancer susceptibility genes are frequently observed in patients with mCRPC. A substantial proportion of patients with mCRPC or their family members would derive clinical utility from mutation screening. Trial registration number: NCT01953640; Results.
UR - http://www.scopus.com/inward/record.url?scp=84971317366&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84971317366&partnerID=8YFLogxK
U2 - 10.1136/bmjopen-2015-010332
DO - 10.1136/bmjopen-2015-010332
M3 - Article
C2 - 27084275
AN - SCOPUS:84971317366
SN - 2044-6055
VL - 6
JO - BMJ open
JF - BMJ open
IS - 4
M1 - e010332
ER -